Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC) today. The company’s shares closed yesterday at $12.68, close to its 52-week low of $12.58.
Yang observed:
“We reduce our PT from $37 to $34 as we now anticipate a delayed product launch in 1Q21. Our overall thesis remains intact – with a longer duration product, DAXI could potentially become the new standard of care.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 11.5% and a 44.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $32.33.
See today’s analyst top recommended stocks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $40.62 million. In comparison, last year the company had a GAAP net loss of $35.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.